MARKET

NEUP

NEUP

Neuphoria Therapeutics Inc
NASDAQ
4.400
-0.170
-3.72%
After Hours: 4.400 0 0.00% 17:58 06/29 EDT
OPEN
4.550
PREV CLOSE
4.570
HIGH
4.595
LOW
4.310
VOLUME
122.40K
TURNOVER
--
52 WEEK HIGH
21.40
52 WEEK LOW
3.645
MARKET CAP
23.78M
P/E (TTM)
-0.5020
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NEUP last week (0622-0626)?
Weekly Report · 21h ago
Neuphoria Therapeutics in Talks to Be Acquired by Scancell Holdings
Dow Jones · 3d ago
NEUPHORIA THERAPEUTICS - CONFIRMS DISCUSSIONS ON POTENTIAL ACQUISITION BY SCANCELL, WHICH WOULD BECOME NASDAQ-LISTED
Reuters · 3d ago
Neuphoria Therapeutics confirms merger discussions with Scancell Holdings
TipRanks · 3d ago
Neuphoria Therapeutics Confirms Discussions With Scancell Holdings About Potential Acquisition; Financial Terms Undisclosed
Benzinga · 3d ago
Neuphoria says it is in talks with Scancell on potential acquisition
PUBT · 3d ago
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Barchart · 3d ago
Weekly Report: what happened at NEUP last week (0615-0619)?
Weekly Report · 06/22 10:12
More
About NEUP
Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Webull offers Neuphoria Therapeutics Inc stock information, including NASDAQ: NEUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEUP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NEUP stock methods without spending real money on the virtual paper trading platform.